RIN-PH-202: An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE OL)

Study Overview

The purpose of this study is to evaluate the safety and efficacy of inhaled treprostinil in patients with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE).

Must have previously participated in study RIN-PH-201.

Study Description

The purpose of this study is to provide or continue to provide inhaled treprostinil to subjects who completed RIN-PH-201.

IRB Number: 1602009433
Research Study Identifier: TX6184
Principal Investigator: William Harvey, MD

Recruitment Status

Closed

Contact the research team to learn more about this study.

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Closed

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176

RIN-PH-202: An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE OL)

Study Overview

Study Description

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

Volunteer Registry